MedTrace Logo

Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer

NCT05841706 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2025-06-10

No results posted yet for this study

Summary

This clinical trial tests the the feasibility of testing a red blood cell transfusion threshold for improved quality of life for patients undergoing a pancreatectomy for pancreatic cancer. Pancreatectomy can be associated with significant blood loss. Blood loss can result in clinically important anemia causing fatigue. Pancreatic cancer itself can be associated with malnutrition and fatigue. Having a red blood cell transfusion threshold that results in a more liberal use of transfusions may improve quality of life for patients undergoing a pancreatectomy for pancreatic cancer.

Conditions

  • Resectable Pancreatic Carcinoma

Interventions

BIOLOGICAL

Arm I Packed Red Blood Cell Transfusion (Hgb < 7 g/dL)

Receive conservative transfusion strategy (Hgb \< 7 g/dL)

BIOLOGICAL

Arm II Packed Red Blood Cell Transfusion (Hgb < 9 g/dL)

Receive liberal transfusion strategy (Hgb \< 9 g/dL)

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

X-Ray Imaging

Undergo x-ray imaging

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

OTHER

Survey Administration

Ancillary studies

PROCEDURE

Pancreatectomy

surgical removal of all or part of pancreas

Sponsors & Collaborators

  • Jonsson Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Edward Livingston, MD · University of California at Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-10
Primary Completion
2025-03-17
Completion
2025-03-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05841706 on ClinicalTrials.gov